5 completed, 1 active not recruiting, 1 withdrawn. 5 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 4, Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow perfluorohexyl-octan: new trials by email Literature Review of perfluorohexyl-octan trials Research Report on perfluorohexyl-octan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease SYSTANE® PRO, MIEBO™ (Perfluorohexyloctane, PFHO) - Dry Eye Disease (DED) | Phase 4 | Completed | Indiana University | 269 | 2026-02-18 | 2026-08-19 |
| A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease Lifitegrast/perfluorohexyloctane (PFHO) - Dry Eye Disease | Phase 3 | Withdrawn | Bausch & Lomb Incorporated | 2025-12-01 | 2025-12-10 | |
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane - Dry Eye Disease | Phase 2 | Completed | Bausch & Lomb Incorporated | 443 | 2025-10-24 | 2026-07-14 |
| A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. Miebo, Saline - Dry Eye | Phase 4 | Active not recruiting | Bausch & Lomb Incorporated | 216 | 2024-07-31 | 2024-12-17 |
| A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy Miebo - Dry Eye | Phase 4 | Completed | Bausch & Lomb Incorporated | 97 | 2024-04-30 | 2026-07-06 |
| A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease Miebo - Dry Eye | Phase 4 | Completed | Bausch & Lomb Incorporated | 99 | 2024-02-28 | 2025-10-21 |
| Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Miebo - Dry Eye, Dry Eye, Evaporative | Phase 4 | Completed | Gordon Schanzlin New Vision | 49 | 2023-09-21 | 2024-04-09 |
Bausch & Lomb Incorporated (5) · Gordon Schanzlin New Vision (1) · Indiana University (1)
United States (6)